Briefing
A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR study.
Median DFS was 9.30 vs 5.55 months (HR 0.79, 95% CI 0.60-1.05; P=0.107); the primary endpoint was not met. The abstract reports a more pronounced benefit in resected oligometastatic stage IV disease and a trend toward greater DFS benefit at higher baseline MTM/mL. Grade >=3 adverse events occurred in 73.0% vs 3.3%. OS data were immature (24 events).
- Design: LBA
- n: 243 randomized (122 FTD/TPI, 121 placebo); 96.3% had received standard-of-care postoperative therapy
- Assay: Signatera (Natera), personalized tumor-informed